Fintel on MSN
Immatics NV announces updated phase 1 data for IMA203CD8 with 51% objective response rate
Immatics N.V. announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy across multiple solid tumor types. As of the August 7, 2026 data cutoff, 98 heavily pretreated patients across ...
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - Glenstar Minerals Inc. (CSE: GSTR) (OTCQB: GSTRF) (FSE: VO20) ("Glenstar" or the "Company") announces that it has completed the Phase 1 ...
SHELTON, CT, April 30, 2024 (Newswire.com) - NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results